Welcome to our dedicated page for Davita SEC filings (Ticker: DVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicare rate shifts, dialysis quality scores, and clinical trial liabilities make DaVita’s SEC disclosures some of the most intricate in healthcare. Parsing a 300-page annual report or tracking last-minute 8-K updates can distract from real analysis. Stock Titan solves that problem by converting dense text into plain-English takeaways, so understanding DaVita SEC documents with AI feels effortless.
Whether you need a DaVita annual report 10-K simplified for reimbursement risk, a quick look at the latest DaVita quarterly earnings report 10-Q filing, or an alert on DaVita 8-K material events explained, every disclosure lands here seconds after EDGAR posts. Our platform instantly tags DaVita insider trading Form 4 transactions and streams DaVita Form 4 insider transactions real-time, letting you spot executive moves before the market reacts. AI-powered summaries highlight patient-mix trends, segment margins, and legal contingencies so you can move from document to decision in minutes.
Use these insights to:
- Monitor DaVita executive stock transactions Form 4 ahead of CMS rulings
- Compare dialysis economics with peer benchmarks through our DaVita earnings report filing analysis
- Review the DaVita proxy statement executive compensation to see how incentives align with patient outcomes
Form 4 summary: Berkshire Hathaway Inc. and Warren E. Buffett reported an insider sale of DaVita Inc. (DVA) common stock.
Key facts:
- Transaction date: 07/31/2025.
- Sold 1,635,962 shares of Common Stock at $140.6052 per share.
- Amount of securities beneficially owned following the transaction: 32,160,579 (indirect).
- Footnote ownership: 15,528,491 shares held by Government Employees Insurance Company (GEICO), and 16,632,088 shares held by two pension plans (BNSF Master Retirement Trust: 6,100,000; Berkshire Hathaway Inc. Consolidated Pension Plan: 10,532,088).
- Form signed by Warren E. Buffett on 08/04/2025.
DaVita Inc. (DVA) Form 4: Chief Compliance Officer James O. Hearty sold 2,351 common shares on 07/23/2025 at $150.00 each under a pre-arranged Rule 10b5-1 trading plan adopted 03/17/2025. The transaction reduced his direct holdings from an estimated 28,389 to 26,038 shares, a decline of roughly 8.3%. No derivative securities were involved. The filing was signed by an attorney-in-fact on 07/24/2025.
The sale represents a modest portion of the insider’s stake and was executed via an automated plan, which may limit informational value regarding management’s outlook. Investors typically monitor insider activity for sentiment signals, trading-plan usage, and potential supply impacts on the stock’s float.
FAQ
What is the current stock price of Davita (DVA)?
What is the market cap of Davita (DVA)?
